Evidence map›Paper›PMID 29742960›Full record

Trial reportJournal of neurotrauma2018

Amantadine Did Not Positively Impact Cognition in Chronic Traumatic Brain Injury: A Multi-Site, Randomized, Controlled Trial.

Flora M Hammond, Mark Sherer, James F Malec, Ross D Zafonte, Sureyya Dikmen, Jennifer Bogner, Kathleen R Bell, Jason Barber, Nancy Temkin

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of neurotrauma, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Recent advances in traumatic brain injury.Journal of neurology · 2019
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Flora M Hammond1 Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine , Indianapolis, Indiana.
Mark Sherer4 TIRR Memorial Hermann , Houston, Texas.
James F Malec1 Department of Physical Medicine and Rehabilitation, Indiana University School of Medicine , Indianapolis, Indiana.
Ross D Zafonte5 Spaulding Rehabilitation Hospital , Boston, Massachusetts.
Sureyya Dikmen6 Department of Rehabilitation Medicine, University of Washington , Seattle, Washington.
Jennifer Bogner7 Department of Physical Medicine and Rehabilitation, The Ohio State University , Columbus, Ohio.
Kathleen R Bell6 Department of Rehabilitation Medicine, University of Washington , Seattle, Washington.
Jason Barber9 Department of Neurological Surgery, University of Washington , Seattle, Washington.
Nancy Temkin9 Department of Neurological Surgery, University of Washington , Seattle, Washington.
University of Washington · USRehabilitation Hospital of Indiana · USMemorial Hermann Institute for Rehabilitation and Research Foundation · USNeurological Surgery · USSpaulding Rehabilitation Hospital · USThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite limited evidence to support the use of amantadine to enhance cognitive function after traumatic brain injury (TBI), the clinical use for this purpose is highly prevalent and is often based on inferred belief systems. The aim of this study was to assess effect of amantadine on cognition among individuals with a history of TBI and behavioral disturbance using a parallel-group, randomized, double-blind, placebo-controlled trial of amantadine 100 mg twice-daily versus placebo for 60 days. Included in the study were 119 individuals with two or more neuropsychological measures greater than 1 standard deviation below normative means from a larger study of 168 individuals with chronic TBI (>6 months post-injury) and irritability. Cognitive function was measured at treatment days 0, 28, and 60 with a battery of neuropsychological tests. Composite indices were generated: General Cognitive Index (included all measures), a Learning Memory Index (learning/memory measures), and Attention/Processing Speed Index (attention and executive function measures). Repeated-measures analysis of variance revealed statistically significant between-group differences favoring the placebo group at day 28 for General Cognitive Index (p = 0.002) and Learning Memory Index (p = 0.001), but not Attention/Processing Speed Index (p = 0.25), whereas no statistically significant between-group differences were found at day 60. There were no statistically significant between-group differences on adverse events. Cognitive function in individuals with chronic TBI is not improved by amantadine 100 mg twice-daily. In the first 28 days of use, amantadine may impede cognitive processing. However, the effect size was small and mean scores for both groups were generally within expectations for persons with history of complicated mild-to-severe TBI, suggesting that changes observed across assessments may not have functional significance. The use of amantadine to enhance cognitive function is not supported by these findings.

Indexed as

AdultAgedAmantadineBrain Injuries, TraumaticBrain Injury, ChronicCognitionDopamine AgentsDouble-Blind MethodFemaleHumansMaleMiddle AgedAmantadineDopamine Agentsamantadineattentionbrain injuriescognitionexecutive functionmemory

Identifiers

PMID29742960
PMCPMC6157374
OpenAlexW2799793494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.